

Title	In vivo dynamics of hard tissue-forming cell origins: Insights from Cre/loxP-based cell lineage tracing studies
Author(s)	Mizoguchi, T
Journal	The Japanese dental science review, 60: 109-119
URL	http://hdl.handle.net/10130/6548
Right	This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Description	



In vivo dynamics of hard tissue-forming cell origins: Insights from Cre/loxP-based cell lineage tracing studies[☆]

Toshihide Mizoguchi¹

Oral Health Science Center, Tokyo Dental College, 2–9-18 Kanda-Misakicho, Chiyoda-ku, Tokyo 101-0061, Japan

ARTICLE INFO

Keywords:

Cell lineage tracing analysis
Cre/loxP
Skeletal stem cells
LepR
Gli1
Axin2

ABSTRACT

Bone tissue provides structural support for our bodies, with the inner bone marrow (BM) acting as a hematopoietic organ. Within the BM tissue, two types of stem cells play crucial roles: mesenchymal stem cells (MSCs) (or skeletal stem cells) and hematopoietic stem cells (HSCs). These stem cells are intricately connected, where BM-MSCs give rise to bone-forming osteoblasts and serve as essential components in the BM microenvironment for sustaining HSCs. Despite the mid-20th century proposal of BM-MSCs, their *in vivo* identification remained elusive owing to a lack of tools for analyzing stemness, specifically self-renewal and multipotency. To address this challenge, Cre/loxP-based cell lineage tracing analyses are being employed. This technology facilitated the *in vivo* labeling of specific cells, enabling the tracking of their lineage, determining their stemness, and providing a deeper understanding of the *in vivo* dynamics governing stem cell populations responsible for maintaining hard tissues. This review delves into cell lineage tracing studies conducted using commonly employed genetically modified mice expressing Cre under the influence of LepR, Gli1, and Axin2 genes. These studies focus on research fields spanning long bones and oral/maxillofacial hard tissues, offering insights into the *in vivo* dynamics of stem cell populations crucial for hard tissue homeostasis.

1. Introduction

Although bone tissues may seem dormant, they undergo constant remodeling and are stringently regulated by osteoclastic bone resorption and osteoblastic bone formation, ensuring the maintenance of both quantity and quality [1–3]. Because the lifetime of mature osteoblasts is limited, a constant supply of osteoblasts from undifferentiated progenitor cells is required to maintain osteoblasts and compensate for resorbed bone tissues [4,5]. The notion that the stem cell fraction responsible for osteoblast generation resides in the bone marrow (BM) has been a longstanding concept dating back to the mid-20th century. Since the 1960s, intensive investigations by Friedenstein et al. [6–9] have progressively unveiled the presence of stem cells within the BM. Their seminal work demonstrated that subcutaneous transplantation of BM cells induces the formation of bone tissue with hematopoiesis, proposing the existence of an undifferentiated cell fraction within the BM capable of regenerating both the bone and marrow environment. Additionally, culturing BM cells at low density revealed the emergence of colonies from a single fibroblast-like cell, identified as colony-forming unit

fibroblasts (CFU-F). This experimental outcome suggests that individual cells form colonies owing to their inherent ability to self-renew under culture conditions. Furthermore, cells derived from a single CFU-F exhibited multipotent differentiation into various lineages, including osteoblasts, adipocytes, and chondrocytes; consequently, these CFU-F-forming cells were classified as stem cells within the BM. Caplan [10] and Pittenger et al. [11] later coined the term “BM mesenchymal stem cells (MSCs)” for these BM cell fractions with CFU-F capacity. However, objections arose as not all cells derived from CFU-F displayed self-renewal and multidifferentiation abilities, raising concerns about the definition of CFU-F as a stem cell [12]. Addressing this issue, the International Society for Cellular Therapy (ISCT) recommends the term “Multipotent Mesenchymal Stromal Cells” for fibroblastic culture dish-adherent cells exhibiting CFU-F capacity, irrespective of tissue origin [13]. Additionally, in cases where the cell population is anticipated to encompass both progenitor and stem cells, the term “Mesenchymal Stem and Progenitor cells” is employed as an analogy to the hematopoietic system [14]. The designation “skeletal stem cells” has long been proposed based on their *in vivo* properties [15,16], and this

[☆] Scientific field of dental Science.

E-mail address: tmizoguchi@tdc.ac.jp.

¹ +81-3-8380-9114

term has been utilized in studies identifying the osteogenic stem cell population in humans and mice through the combination of cell surface protein markers [17,18]. Based on this background, this review adopts the term “Skeletal Stem and Progenitor cells (SSPCs)” to denote stem cells contributing to hard tissue formation, encompassing the diverse nomenclature and evolving understanding within this field.

The described *in vitro* approach for assessing cell stemness through the analysis of CFU-F and pluripotency remains a valuable method frequently employed by researchers. Nonetheless, its limitations become apparent when attempting to demonstrate stemness *in vivo*. The advent of cell lineage tracking techniques, employing Cre/loxP-based strategies in genetically modified mice, has led to a new era of stem cell research by enabling the direct demonstration of *in vivo* stemness [19]. In this method, cells can be labeled depending on the expression of Cre recombinase under the control of a promoter for specific cell markers, and the stemness (self-renewal and multipotency) of the labeled cells was examined using *in vivo* tracking. Over the past few years, researchers have attempted to understand the hierarchical relationships between BM mesenchymal cell populations *in vivo* using this technique and have identified specific markers to detect SSPC populations in bone tissues

[20,21].

In addition to limb bones, hard tissue-forming cells also originate in oral and cranio-maxillofacial areas, such as dental pulp (DP) [22–24], periodontal ligament (PDL) [25–29], alveolar bone (AB) [30,31], and cranial sutures [32]. Recent advancements in cell lineage tracing approaches have provided insights into the *in vivo* dynamics of these tissues. Various Cre-expressing genetically modified mice have been employed in hard tissue stem cell research, with a particular emphasis on the utility of leptin receptor (LepR), glioblastoma (Gli1), and Axin2-induced Cre-expressing mice [33–35]. These models prove especially beneficial for conducting a wide range of hard tissue experiments, including limb and oral/cranio-maxillofacial bone studies.

This review begins by outlining the methodology of cell lineage tracing analysis using genetically modified mice, followed by a historical overview of BM SSPC research, which has significantly progressed with the integration of cell lineage tracing technology. Additionally, the review presents recent findings on the *in vivo* dynamics of SSPCs within limb and oral/cranio-maxillofacial hard tissues, focusing on LepR-, Gli1-, and Axin2-induced Cre-expressing mice. Table 1 provides a comprehensive list of representative studies analyzing the origin of hard tissue-

Table 1
Representative studies of cell lineage-tracing analysis in LepR⁺, Gli1⁺, or Axin2⁺ populations.

A. Long bones				
Driver	Time point of induction	Cre-expressing cells	Contribution	References
<i>LepR-Cre</i>	• N/A	• Perivascular BM stromal cells	• Osteoblasts, osteocytes, adipocytes, and regenerative chondrocytes	[57,58]
<i>Gli1-CreER^{T2}</i>	• Three consecutive days at 4 weeks old [99] • Every other day for 7 days at 8 weeks old [104]	• MMPs beneath the growth plate [99] • Periosteum [99,104]	• Osteoblasts, LepR ⁺ stromal cells, and adipocytes in the BM of growing bone [99] • Fracture callus [99,104]	[99,104]
<i>Axin2-CreER^{T2}</i>	• One time at P1 [132] • Five consecutive days at 8 weeks old [133] • One time at P6 [134]	• Perivascular BM stromal cells [132] • Periosteum [133] • Outermost layer of the growth plate [134]	• Osteoblasts, osteocytes, and adipocytes in the BM of growing bone [132] • Fracture callus [132,133] • Growth plate chondrocytes [134]	[132–134]
B. Dental pulp				
Driver	Time point of induction	Cre-expressing cells	Contribution	References
<i>Gli1-CreER^{T2}</i>	• Three consecutive days at 4–6 weeks old	• Dental mesenchyme around cervical loop of incisors	• Whole dental mesenchyme of incisors	[111]
<i>Axin2-CreER^{T2}</i>	• Three consecutive days at 6 weeks old	• Dental pulp cells at the site of damaged dentin in the molars	• Reparative odontoblast-like cells	[141]
C. Periodontal ligament				
Driver	Time point of induction	Cre-expressing cells	Contribution	References
<i>LepR-Cre</i>	• N/A	• Perivascular mesenchymal cells in PDL	• AB osteocytes and cementocytes • Regenerated bone in the tooth extraction socket	[87]
<i>Gli1-CreER^{T2}</i>	• Two consecutive days at 5–8 weeks old [113] • Two consecutive days at 3 weeks old [114] • Two consecutive days at 4 or 8 weeks old [115–117]	• PDL in the apical region surrounding the NVB	• PDL fibroblasts, cementoblasts, and osteoblasts [113–115] • Regenerated bone in the tooth extraction socket [116] • Osteoblasts, osteocytes, and fibroblasts on the traction side of orthodontic treatment [117]	[113–117]
<i>Axin2-CreER^{T2}</i>	• Three consecutive days at 5 weeks old [158] • One time at 4 weeks old [162, 163]	• Mesenchymal cell population randomly distribute throughout the PDL	• Regenerated bone in the tooth extraction socket [158] • Cementoblasts and cementocytes [162] • Osteoblasts and osteocytes on the traction side of orthodontic treatment [163]	[158,162,163]
D. Alveolar bone				
Driver	Time point of induction	Cre-expressing cells	Contribution	References
<i>LepR-Cre</i>	• N/A	• Mesenchymal cells in alveolar BM	• Osteoblasts and osteocytes in AB, and regenerated bone in the extraction socket	[90]
<i>Gli1-CreER^{T2}</i>	• Two consecutive days starting at 6 weeks old	• Perivascular mesenchymal cells in alveolar BM	• Osteoblasts and osteocytes in regenerated bone in the extraction socket	[125]
E. Calvarial suture				
Driver	Time point of induction	Cre-expressing cells	Contribution	References
<i>Gli1-CreER^{T2}</i>	• Four consecutive days at 4 weeks old	• Suture mesenchymal cells	• Calvarial osteoblasts, periosteum, and dura	[109]
<i>Axin2-rtTA</i>	• Three consecutive days starting at P25	• Mesenchymal cells localized in the center of the suture	• Suture mesenchyme, osteoblasts, and osteocytes • Suture mesenchyme and osteocytes in regenerated calvarial bone	[135]

BM, bone marrow; MMPs, metaphyseal mesenchymal progenitors; P, postnatal; AB, alveolar bone; PDL, periodontal ligament; NVB, neurovascular bundle.

forming cells using the mouse lines discussed in this review.

2. Cell lineage tracing analysis using Cre/loxP techniques

The advent of Cre/loxP-based genetic modification technology has facilitated the specific labeling of cells *in vivo*, enabling the monitoring of their dynamics throughout their lifespan. The DNA recombinase Cre can excise the DNA region flanked by loxP sequences. Consequently, when a stop codon, positioned between loxP sequences, is situated upstream of a reporter gene, such as tdTomato (tdTom), the excision of the stop codon occurs upon Cre expression, inducing the expression of the reporter gene. The gene inserted at the Rosa26 locus is expressed systemically [36,37]. Therefore, mice harboring the specified gene (loxP-stop-loxP-tdTom) at the Rosa26 locus possess a Cre/loxP-based reporter system in a systemic manner (ROSA26-loxP-stop-loxP (R26)-tdTom) [38]. Consequently, only the Cre-expressing target cells are specifically labeled in the mouse body (Fig. 1A). Additionally, the timing of cell labeling can be artificially controlled using CreER^{T2}, a mutant of the estrogen receptor, combined with Cre (Fig. 1B). CreER^{T2} remains outside the nucleus in the absence of tamoxifen (Tam); however, upon binding to Tam, it translocates to the nucleus and cleaves the loxP site. As a result, the target cells are labeled in response to Tam administration in mice [39]. Owing to the half-life of Tam being less than 48 h, cell labeling is transiently induced. This system allows analysis of the persistence (self-renewal) and differentiation of labeled cells into progeny (pluripotency) to demonstrate their stemness *in vivo*.

3. Development of SSPC research in parallel with hematopoietic stem cell niche research

BM is a unique tissue containing two types of stem cells, SSPCs and hematopoietic stem cells (HSCs). The field of SSPC research has progressed alongside HSCs, as illustrated in the subsequent historical account.

The stem cell niche is believed to create a microenvironment that sustains stem cell properties, such as self-renewal capacity and multi-lineage ability [40]. In 1978, Schofield [41] proposed the existence of a stem cell niche in the BM tissue that regulates HSCs. Since then, hematologists worldwide have actively sought the identity of cells comprising the HSC niche. In the early-2000 s, multiple research groups reported that osteoblasts were responsible for the HSC niche [42–44]. However, ongoing controversy surrounds whether osteoblasts truly function as niche cells for HSCs [45–48]. Méndez-Ferrer et al. [49] observed the BM tissue of transgenic mice expressing GFP under the control of the nestin (Nes) promoter and enhancer, detecting Nes-GFP⁺ cells as perivascular stromal cells. Depleting Nes⁺ stromal cells *in vivo* using the Cre/loxP-based strategy significantly reduced the number of HSCs in the BM, supporting the conclusion that Nes⁺ stromal cells serve as HSC niche cells. In contrast, in 2003, Ara et al. [50] reported that the chemokine C-X-C chemokine ligand 12 (CXCL12) (also known as SDF-1: stromal cell-derived factor-1) is a necessary factor for BM engraftment of HSCs in developing BM tissue. Perivascular cells, identified as a source of CXCL12 in GFP knock-in mice in the second exon of CXCL12, were associated with BM HSCs. Depletion of CXCL12⁺ perivascular cells (referred to as CXCL12-abundant reticular (CAR) cells) significantly




Fig. 1. System for cell lineage tracing analysis using Cre/loxP strategy. (A) When a stop codon sandwiched by a loxP sequence is cut out *via* Cre recombinase controlled by a cell-specific promoter, the expression of the reporter gene is induced. The gene inserted at the Rosa26 locus is systemically expressed. Therefore, the mice with the gene (loxP-stop-loxP-reporter gene) at the Rosa26 locus will have the Cre/loxP-based reporter system in a systemic manner. Thus, only Cre-expressing target cells can be specifically labeled by the induced reporter gene in the mouse body. (B) The timing of cell labeling can be artificially controlled using the CreER^{T2} system. CreER^{T2} resides outside the nucleus without tamoxifen (Tam); however, when bound to Tam, it migrates into the nucleus and cleaves the loxP site. Hence, the target cells are labeled in response to the Tam administration to the mice. The half-life of Tam is less than 48 h, so cell labeling is induced transiently.

decreased BM HSCs, suggesting that CAR cells also function as HSC niche cells [51]. Crucially, both Nes⁺ stromal and CAR cells were shown to possess SSPC capacities and exhibit roles as the components of the HSC niche [49,51]. Similar to mouse BM tissue, human-derived melanoma cell adhesion molecule (MCAM/CD146)⁺ BM perivascular cells demonstrated the capacity for both SSPCs and the HSC niche, as evidenced by cell transplantation experiments in immunocompromised mice [52]. Therefore, the experimental histories of SSPCs and HPCs are closely intertwined. In the pursuit of HSC niche cells, researchers have successfully pinpointed populations of SSPCs.

4. Identification of SSPCs using LepR-Cre mice

Leptin is a peptide hormone expressed by adipocytes that has been identified as a causative gene of obesity in *ob/ob* mice [53]. Similarly, LepR has been identified as the cause of early obesity in *db/db* mice [54]. Leptin exerts antifeedant activity by binding to LepR expressed on neurons in the hypothalamus [55]. Lineage tracing analysis performed on LepR-Cre knock-in mice [34] revealed that LepR can be used as a marker of SSPCs in the adult stage.

4.1. Identification of long bone-derived LepR⁺ SSPCs

In addition to the Nes⁺ stromal and CAR cells described above, Ding et al. reported LepR⁺ stromal cells as HSC niche cells in the BM [56]. LepR⁺ stromal cells are perivascularly localized and function as an HSC niche through stem cell factor (SCF) expression, which is necessary for HSC maintenance in the BM. LepR⁺ stromal cells were detected as tdTom⁺ cells in the BM of LepR-Cre; R26-tdTom mice (Fig. 2A). *In vivo* lineage tracing analysis revealed that LepR⁺ stromal cells differentiate into osteoblasts, adipocytes, and fractured callus chondrocytes, indicating that these cells have the capacity for SSPCs, similar to Nes⁺ stromal cells and CAR cells [57,58]. Researchers have shown that most LepR⁺ stromal and CAR cells overlap [59,60]. In addition, BM Nes-GFP⁺ stromal cells have been classified into two subpopulations, Nes-GFP^{bright} and Nes-GFP^{dim}, based on their GFP expression levels. It has also been shown that Nes-GFP^{dim} stromal cells overlapped with LepR⁺/CAR cells [61]. In contrast, Nes-GFP^{bright} stromal cells were found in peri-arterial and metaphyseal BM tissues [62] (Fig. 3). Periarterial Nes-GFP^{bright} stromal cells are positive for the pericyte marker neural/glia antigen 2

Confocal images from a 5-month-old male *LepR-Cre; R26-tdTom* mouse




Fig. 2. LepR⁺ SSPCs labeled by LepR-Cre. Z-stack confocal images of thick femur (A) and maxillary first molar (B) sections from 5-month-old male LepR-Cre; R26-tdTom mice. The squares in the upper schema indicate the area of the Z-stack confocal images. White arrows: LepR⁺ SSPCs; White arrowheads: LepR⁺ SSPC-derived osteocytes; yellow arrows: LepR⁺ SSPC-derived cementocytes. BM, bone marrow; CB, cortical bone; CM, cementum; AB, alveolar bone; PDL, periodontal ligament; DIC, differential interference contrast. Scale bar = 50 μ m (A and B).

Femur sections of a 3-week-old male *Nes-GFP* mouse




Fig. 3. Subpopulation of Nes-GFP⁺ cells in long bone detecting as Nes-GFP^{bright} and Nes-GFP^{dim}. Z-stack confocal images of thick femur sections from 3-week-old male *Nes-GFP* mice. The square in the upper schema indicates the area of the Z-stack confocal image. Numbered panels represent the magnified views of the boxed areas. Nes-GFP⁺ stromal cells were distinguished as Nes-GFP^{bright} or Nes-GFP^{dim} based on their GFP expression levels. Nes-GFP^{dim} stromal cells overlap with LepR⁺/CAR cells. Nes-GFP^{bright} stromal cells were observed in the periarterial and metaphyseal regions. Periarterial Nes-GFP^{bright} cells are suggested to be HSC niche cells. The characteristics of Nes-GFP^{bright} stromal cells in the metaphyseal BM tissue remain unclear. White arrows: Metaphyseal Nes-GFP^{bright} stromal cells; white arrowheads: Nes-GFP^{dim} stromal cells; yellow arrows: Periarterial Nes-GFP^{bright} stromal cells. BM, bone marrow; GP, growth plate; DIC, differential interference contrast. Scale bar = 200 μ m (upper panel), 50 μ m (lower panels).

(NG2) and have been suggested to be HSC niche cells [61]. However, the characteristics of Nes-GFP^{bright} stromal cells in metaphyseal BM tissue remain unclear; therefore, further analysis is warranted to comprehensively understand BM stromal populations.

4.2. Differences in the characteristics of LepR⁺ SSPCs between growth and adult stages

Although LepR⁺ stromal cells demonstrate the capability of SSPCs, the presence of LepR⁺ SSPC-derived osteoblasts is rarely observed in neonatal bone tissue [57,58]. These observations imply that neonatal osteoblasts may originate from cell populations distinct from LepR⁺ SSPCs, indicating a developmental stage-dependent variation in the source of osteoblasts. Mizuhashi et al. [63] reported that growth plate resting zone chondrocytes, labeled with parathyroid hormone-related protein (PTHrP)-CreER^{T2}, serve as the source of osteoblasts in developing bone tissue. These resting zone chondrocytes undergo subsequent differentiation into proliferating and hypertrophic chondrocytes, ultimately migrating to the BM through osteoblastogenesis. Furthermore, Shu et al. [64] demonstrated that osteoblasts in the early postnatal period differentiate from growth plate chondrocytes labeled with Aggrecan-CreER^{T2}. However, their origin shifts to LepR⁺ SSPCs after adolescence, as determined using dual-recombinase fate-mapping systems. This technique involves labeling two cell fractions with different

fluorescent dyes, enabling the simultaneous tracing of their lineages. These results suggest that LepR⁺ SSPCs predominantly contribute to bone remodeling with relatively modest bone formation rather than playing a significant role during the bone growth phase characterized by substantial bone formation. Consequently, LepR⁺ SSPCs may collaboratively participate in bone remodeling alongside osteoblasts and osteoclasts in adulthood to old age. Additionally, the association between age-related loss of osteogenic potential and cellular senescence in LepR⁺ SSPCs is intriguing; however, the details remain unknown and necessitate further investigation.

4.3. Regulatory mechanism of LepR⁺ SSPC differentiation

Teriparatide, a biologically active amino acid 1–34 fragment of human PTH [hPTH (1–34)], demonstrates bone anabolic activity and is clinically utilized for osteoporosis treatment [65,66]. Teriparatide treatment significantly increases the number of mature osteoblasts in bone tissue, contributing to the mechanisms of bone anabolism [67]. Although one mechanism involves the induction of osteoblastic differentiation of SSPCs by teriparatide, the details remain unclear. Cell lineage tracing analysis revealed that teriparatide treatment expedites the differentiation of LepR⁺ SSPCs into osteoblasts [68]. Conversely, teriparatide inhibits differentiation into adipocytes, another lineage of LepR⁺ SSPCs [69]. Consistent with these findings, conditional deletion of the PTH/PTHrP receptor in mesenchymal cells throughout bone tissue reduced bone formation increased BM adipocytes [70]. This suggests that part of teriparatide's bone anabolic effect involves lineage switching from adipocytes to osteoblasts.

Does the LepR expressed in SSPCs influence the lineage differentiation? Deletion of LepR in mesenchymal cells throughout long bone tissue using Prx1-Cre; floxed-LepR mouse lines reportedly increased bone formation rate, elevated bone mass, and reduced adipocyte numbers when compared with those in the controls [71]. These findings indicate that peripheral leptin/LepR signaling in SSPCs negatively regulates osteoblastic differentiation and positively influences adipocytic differentiation. Similarly, leptin has been reported to inhibit osteoblast differentiation *via* the sympathetic nervous system [72,73]; however, the relationship between leptin signaling in peripheral and central pathways remains unclear. In contrast, bone mass in leptin-dysfunctional ob/ob mice is significantly reduced when compared with that in wild-type mice [74], and leptin reportedly promotes osteoblastogenesis in the periphery [75]; therefore, further investigations are required to determine the regulatory mechanisms of leptin signaling in lineage differentiation.

Additionally, certain transcription factors governing the lineage differentiation of LepR⁺ SSPCs have been identified. Conditional deletion of forkhead box c1 (Foxc1) in LepR⁺ SSPCs (LepR-Cre; floxed-Foxc1) resulted in increased numbers of BM adipocytes, indicating that Foxc1 negatively regulates adipocyte differentiation in LepR⁺ SSPCs [60]. Conversely, the transcription factor early B-cell factor 3 (Ebf3) inhibits osteoblast differentiation from LepR⁺ SSPCs [76]. In pathological conditions, LepR⁺ SSPCs serve as the origin of myofibroblasts induced in primary myelofibrosis, a disorder of BM hematopoiesis [77], and runt-related transcription factors (Runx) 1 and 2 have been shown to suppress their differentiation [78].

The regulatory mechanism of the lineage differentiation of LepR⁺ SSPCs into various cell types *in vivo* is gradually becoming clear at the molecular level. Further exploration of the signaling cascades and age-dependent epigenetic changes of these molecules is expected to enhance our understanding of the pathological mechanisms underlying bone regulation by LepR⁺ SSPCs.

4.4. Heterogeneity of LepR⁺ SSPCs

Single-cell RNA sequencing (scRNA-seq) revealed that long bone-derived LepR⁺ SSPCs comprise heterogeneous cell populations with distinct gene profiles [79–83]. CAR cells/LepR⁺ SSPCs were shown to be

classified into “Adipo-CAR cells” and “Osteo-CAR cells” based on their genetic profiles [81,82]. These two populations have different origins in developmental cartilage primordia, with adipo-CAR cells derived from Distal-less homeobox 5 (Dlx5)⁺ perichondrial cells and osteo-CAR cells derived from Fibroblast growth factor receptor 3 (Fgfr3)⁺ chondrocytes [84]. The Fgfr3⁺ cells are also detected in the endosteum and represent the origin of osteoblasts during young stages [85]. Interestingly, Adipo-CAR was localized only in the central long axis of the BM and contributed to osteoblasts in the trabecular bone but not in the cortical bone [82]. These findings provide an intriguing suggestion that the origin of osteoblasts differs between the cortical and trabecular tissues. Furthermore, a subpopulation of LepR⁺ SSPCs was identified as an osteogenic growth factor, osteolectin⁺, localized in the periarteriolar region [86]. Periarterial osteolectin⁺ LepR⁺ cells not only generate osteoblasts but also regulate bone volume and lymphocytic differentiation by sensing mechanical stress. Altogether, the BM cell population labeled with LepR-Cre is composed of heterogeneous subpopulations that can be distinguished by genetic profiling, each of which may cooperate to maintain bone and BM homeostasis.

4.5. LepR⁺ SSPCs localized in PDL and AB

The PDL is a connective tissue required for the attachment of the tooth to the jawbone by penetrating the AB and cementum. PDL contains SSPCs that provide hard tissue-forming cells such as osteoblasts and cementoblasts [29]. Similarly, the marrow space of the AB contains specific SSPCs, which are known to have lower differentiation potential than chondrocytes and adipocytes and higher angiogenic potential than iliac BM-derived SSPCs [30,31]. It has been suggested that SSPCs contribute to jawbone maintenance; however, their *in vivo* dynamics remain unknown. Cell lineage tracing studies have identified LepR⁺ cells in the PDL and AB marrow and demonstrated the contribution of their lineage to hard tissue maintenance.

LepR⁺ cells were detected as tdTom⁺ cells in the PDL of the LepR-Cre; R26-tdTom mice (Fig. 2B). The number of LepR-Cre-labeled PDL cells (LepR⁺ PDL cells) increased with age and differentiated into cementocytes and AB-embedded osteocytes [87]. The contribution of LepR⁺ cells to cementocytes has also been demonstrated using inducible LepR-CreER^{T2} mice [88]. Furthermore, a depletion of low-density lipoprotein receptor-related protein 1 (LRP1) in LepR⁺ cells has been shown to reduce their osteoblastic differentiation and the AB mass [89]. However, the frequency of LepR⁺ PDL cell-derived lineages in hard tissues was less than 20%, suggesting that cell populations other than LepR⁺ PDL cells also provide hard tissue-forming cells in parallel [87]. By contrast, Zhang et al. detected LepR⁺ cells in the AB marrow of LepR-Cre; R26-tdTom mice and showed that these cells differentiated into osteoblasts in response to tooth extraction and contributed to bone regeneration [90]. Furthermore, socket regenerative bone healing was delayed by the depletion of LepR⁺ cells using the Cre/LoxP system. However, the frequency of LepR-Cre-labeled cell-derived osteocytes in the regenerative bone of the extraction sockets was extremely low (<9% of the total), suggesting that the LepR⁺ cell lineage may play an essential role in bone regeneration in addition to providing bone-forming cells [87]. Alternatively, this finding suggests that in addition to LepR⁺ cells in the PDL and AB, other SSPC populations may contribute to bone regeneration in the extraction socket.

In summary, LepR⁺ cells localized in both the PDL and AB marrow may contribute to jawbone maintenance. However, differences in the characteristics of these cell populations are not well understood. Additionally, most cell lineage tracing analyses of the LepR⁺ cell population described above have been performed using non-inducible LepR-Cre mice. In the future, it will be necessary to reanalyze the dynamics of LepR⁺ SSPCs in both limbs and jawbones using LepR-CreER^{T2} mice [64, 88,91].

5. Identification of SSPCs using Gli1-CreER^{T2}

Indian Hedgehog (Hh), one of the three Hh family proteins, is a key regulator of chondrocyte and osteoblast differentiation during endochondral bone development [92–95]. Hh binds to the 7-transmembrane receptor smoothed (smo) and regulates gene expression through the activation or repression of the transcription factor Gli1–3 [96]. Gli1 acts as its own transcriptional target downstream of Hh signaling and upregulates its expression [97,98]. Thus, cells that received Hh signals and contributed to bone development were identified as Gli1-expressing cells. Cell lineage tracing analyses using Gli1-CreER^{T2} knock-in mice [33] have contributed to our understanding of the *in vivo* dynamics of SSPCs, which are detected as Gli1⁺ cells in limb and oral/cranio-maxillofacial hard tissues.

5.1. Gli1⁺ SSPCs contributing to long bone growth

Shi et al. performed a lineage tracing analysis of Gli1⁺ cells using Gli1-CreER^{T2} mice and analyzed their roles in long bone growth [99]. Gli1⁺ cells were only observed just below the growth plate and differentiated into osteoblasts, adipocytes, and LepR⁺ SSPCs during bone growth, and therefore termed “metaphyseal mesenchymal progenitors (MMPs).” These MMPs may act as the origin of osteoblasts subsequent to PTHrP-CreER^{T2}-labeled resting zone chondrocytes during bone development [63]. Osteoblastic differentiation of MMPs was accelerated in response to treatment with teriparatide [100] as well as the aforementioned LepR⁺ SSPCs [68,69]. In addition, gene profiling analysis at the single-cell level revealed that MMPs are composed of four subpopulations characterized by chondrocyte-like osteoprogenitors (COP), preosteoblasts, osteoblasts, and BM adipogenic lineage progenitors. Among these four subpopulations, COP is hierarchically at the top of cell differentiation [100]. Importantly, MMPs are observed only during the growth stage and disappear during adulthood. This suggests that MMPs are SSPCs that specifically contribute to bone growth. These transient SSPC populations may enable the generation of more hard tissue-forming cells and respond to drastic bone formation during bone growth.

5.2. Gli1⁺ SSPCs in the periosteum of long bones

Both BM- and periosteal-derived SSPCs have been proposed to play a role in regenerating fractured limb bones [101,102]. However, the primary question is which populations are predominantly responsible for this healing process. In long bones, there are two pathways for fracture healing: intermembranous ossification, where SSPCs directly differentiate into osteoblasts, contributing to bone formation, and endochondral ossification, occurring through chondrogenic differentiation from SSPCs. The activation of these pathways depends on the degree of bone damage [57,82,101,103]. Drill hole-induced bone defects are mainly repaired through intermembranous ossification, while non-stabilized bicortical fractures induce endochondral ossification, resulting in the formation of a cartilaginous callus outside the bone, replaced by a bony callus and eventually regenerating cortical bone. Although SSPC dynamics during the healing process have been controversial, studies using a Cre/loxP-based strategy have revealed that BM- or periosteum-derived SSPCs are selectively activated depending on the fracture type [104]. Periosteal SSPCs can be specifically labeled using Gli1-CreER^{T2} mice during adulthood [99,104]. In contrast, adiponectin (Adipoq)-Cre-labeled cells overlap specifically with LepR⁺ SSPCs in the BM but not in the periosteum. Chondrocytes and osteoblasts in the fracture callus induced by bicortical fractures originate from periosteal SSPCs, not SSPCs in the BM. Conversely, BM-derived SSPCs, not periosteal SSPCs, contribute to new trabeculae formation within the BM at the fracture site. Similarly, only BM-derived SSPCs contribute to repairing BM trabeculae after drill injuries. Notably, the origins of osteocytes in repaired cortical bone are periosteal SSPCs in bicortical fractures and

BM-derived SSPCs in drill injuries. Additionally, muscle-derived mesenchymal progenitors labeled by Prx1-Cre are suggested to contribute to chondrocytes and osteoblasts in the fracture callus [105].

In summary, various types of SSPCs near the injured site during the fracture healing process sense the extent of damage and flexibly respond to bone healing. It is suggested that SSPCs possess a sensing system for tissue injury and are responsible for appropriate regeneration; however, future studies are required to clarify the details of this mechanism.

5.3. Gli1⁺ SSPCs in the suture regulating the craniofacial bone development

Unlike long bones, which form through endochondral ossification, craniofacial bones are flat bone tissues formed primarily by intermembranous ossification [106]. The cranial bone is composed of flat, dish-shaped bones joined together; these joints are called sutures, which serve as growth centers for intermembranous ossification. Calvarial sutures in humans fuse as they grow; however, in craniosynostosis, the sutures fuse prematurely in infancy. This disease causes delayed brain development owing to abnormal skull growth, resulting in mental retardation, learning disabilities, and cognitive impairment, which significantly reduce the quality of life of the patients [107,108]. It has been suggested that sutures contain SSPC populations that regulate skull growth by osteoblast generation at the osteogenic front, and the disruption of this system leads to the development of craniosynostosis [32]. Although the characteristics of SSPCs in the sutures have long been unclear, Zhao et al. identified SSPCs as Gli1⁺ cells in Gli1-CreER^{T2} mice [109]. Importantly, the depletion of Gli1⁺ SSPCs by the Cre/loxP system induced suture fusion, indicating that Gli1⁺ SSPCs suppress synostosis. Consistent with this finding, the number of suture-derived Gli1⁺ SSPCs was significantly reduced in Twist1 heterozygous deficient mice, a mouse model of Saethre–Chotzen syndrome that presents with craniosynostosis. Furthermore, a therapeutic strategy for craniosynostosis was proposed, showing that cranial suture reconstruction in a craniosynostosis mouse model could be induced by the transplantation of suture-derived Gli1⁺ SSPCs [110]. This reconstructed suture improved the cranial deformities, resulting in mitigated delayed brain development and neurocognitive abnormalities. These findings suggest that Gli1⁺ SSPCs may play a role in maintaining suture homeostasis. Future studies should elucidate their regulatory mechanisms as niche cells and lead to fundamental therapeutic strategies for craniosynostosis.

5.4. Gli1⁺ SSPCs localized in DP, PDL, and AB

Although the presence of SSPC populations in the DP has long been suggested, their *in vivo* dynamics remain unknown [22–24]. As mouse incisors grow continuously throughout life, pulpal SSPCs in the incisors have been assumed to permanently give rise to lineage cells, including odontoblasts, which form dentin tissue. Using Gli1-CreER^{T2} mice, Zhao et al. showed that Gli1⁺ cells detected in the dental mesenchyme around the cervical loop of incisors, which acted as SSPCs that provided the entire pulp mesenchyme to sustain incisor growth [111]. The sensory nerve in the neurovascular bundle (NVB) acts as a microenvironmental niche supporting Gli1⁺ SSPCs by expressing sonic hedgehog (Shh).

However, some studies have reported that Gli1⁺ cells in the PDL around the molars also act as SSPCs [112–117]. PDL-derived Gli1⁺ SSPCs are mainly localized adjacent to the NVB of the root apex and differentiate into osteoblasts, cementoblasts, and PDL fibroblasts to maintain jawbone homeostasis [113–115]. In this process, the activation of Wnt/ β -catenin signaling is required for the differentiation of Gli1⁺ SSPCs into progeny cells [113,114]. Sclerostin is secreted by osteocytes [118], and acts as a Wnt inhibitor by directly binding to the Wnt receptor and LRP5/6 [119–122]. Osteocyte-derived sclerostin expression decreases in response to mechanical loading but increases following release of mechanical stress [123]. Consistently, the release of occlusion force-derived mechanical stress increases the expression of sclerostin in

cementocytes and osteocytes, reducing the lineage differentiation of Gli1⁺ SSPCs and decreasing cementum and AB mass [113]. Conversely, sclerostin levels have been reported to be reduced on the orthodontic traction side [124], suggesting that Wnt/ β -catenin signaling is activated there. Consistent with this finding, osteoblastic differentiation of PDL-derived Gli1⁺ SSPCs was induced on the traction side during orthodontic tooth movement [117]. Furthermore, Gli1⁺ SSPCs in the PDL contribute to bone regeneration after tooth extraction [116]. Meanwhile, perivascular Gli1⁺ SSPCs have also been detected in AB marrow tissue which contributes to extraction socket repair and implant osseointegration in a Wnt/ β -catenin signal-dependent manner [125].

Altogether, Gli1⁺ SSPCs in the jawbone are localized in the DP, PDL, and AB marrow, and they share a similar localization in the vicinity of blood vessels [111,113,125]. Differences in their characteristics remain unclear, and future studies are required to clarify this question.

6. Identification of SSPCs using Axin2-CreER^{T2}

Wnt signaling is an indispensable pathway in bone development [126]. The canonical Wnt signaling is triggered upon the binding of Wnt ligands to the co-receptor, LRP5/6, and frizzled (FZD), leading to β -catenin stabilization. In contrast, in the absence of Wnt ligands, β -catenin is phosphorylated by the multiprotein destruction complex and degraded by the ubiquitin-proteasome, resulting in the signal being turned off. Axin2, a multiprotein destruction complex, is upregulated downstream of the canonical Wnt signaling and creates a negative feedback loop [127,128]. Based on this mechanism, lineage tracing analysis of Wnt signaling-activated cells (Wnt-responsive cells) has been performed using Axin2-CreER^{T2} knock-in mice, and their stemness has been confirmed in various tissues [35,129–131].

6.1. Axin2⁺ SSPCs contributing to long bone growth

To investigate the dynamics of Wnt-responsive cells (Axin2⁺ cells) during long bone growth, cell lineage tracing was performed using Axin2-CreER^{T2} mice [132]. In the early neonatal stage, Axin2⁺ cells were primarily found as BM stromal cells; however, Axin2⁺ cells were not detected in osteoblasts or osteocytes. Subsequently, Axin2⁺ stromal cells differentiate into bone-forming cells with age, and their lineage contributes to bone healing; neonatal BM-derived Axin2⁺ cells are considered SSPCs. Mechanistically, Axin2⁺ SSPCs activate Wnt signaling in an autocrine manner *via* the secretion of Wnt ligands, leading to proliferation and osteoblast differentiation. Similarly, Axin2⁺ cells have been found in the periosteum of long bones as SSPCs, which contribute to bone repair [133]. Additionally, Axin2⁺ cells are detected in the outermost layer of the growth plate in the early neonatal stage, and these cells have been shown to contribute to the lateral growth of cartilage by differentiating into chondrocytes in the growth plate [134]. These Axin2⁺ cartilage progenitors express Wnt, which activates their own canonical Wnt signaling in an autocrine manner, similar to neonatal BM-derived Axin2⁺ SSPCs [132]. As the number of Axin2⁺ cells in the outermost layer of the growth plate decreases with age [134], it is conceivable that Axin2⁺ cells supporting bone development in the perichondrium and BM may reduce their own Wnt expression and complete the bone growth when they transition to the adult stage.

6.2. Axin2⁺ SSPCs in the suture regulating the craniofacial bone development

Maruyama et al. generated Axin2-rtTA (reverse tetracycline transactivator); TRE (tetracycline response element)-Cre; R26-LacZ mice that expressed LacZ in Axin2⁺ cells in response to doxycycline administration and identified cranial suture-derived Axin2⁺ SSPCs [135]. Axin2⁺ cells at postnatal day 28 localize to the center of the suture in a quiescent state and differentiate into sutured mesenchymal cells, calvarial osteoblasts, and osteocytes with aging. In addition, Axin2⁺ SSPCs migrated to

the injury site and contributed to bone healing in response to calvarial bone injury. Furthermore, the deletion of Bmpr1a in Axin2⁺ SSPCs causes craniosynostosis because of decreased Axin2⁺ SSPCs and increased osteoblasts, suggesting that the dynamics of Axin2⁺ SSPCs in sutures are related to the pathogenesis of craniosynostosis [136]. Importantly, among the sutural mesenchymal cells, the Axin2⁺ population had significantly higher expression of Gli1 and LepR, which are known markers of SSPCs [135]. Further studies are needed to clarify the relationship between these marker-positive populations in the suture.

6.3. Axin2⁺ SSPCs in the pulp of molars

Wnt signaling pathways significantly contribute to tissue regeneration processes regulated by tissue-resident stem cells [137–139]. Studies have suggested that Wnt signaling positively regulates damaged dentin regeneration mediated by SSPCs in the DP [140–144]. As described above, odontoblasts are continuously supplied by SSPCs in rodent incisors. However, SSPCs in the molar pulp differentiate into odontoblast-like cells only when dentin is damaged and contribute to dentin healing. Hunter et al. [140] demonstrated that reparative dentin formation is induced in response to molar damage with pulp exposure and that this healing process is enhanced in Axin2 knockout mice, wherein canonical Wnt signaling is activated. Furthermore, treatment with Wnt3a accelerates the formation of both reparative dentin [140] and reactionary dentin (repairing dentin induced without pulp exposure) [144] in rodents. Tideglusib is a small molecule that activates canonical Wnt signaling by inhibiting glycogen synthase kinase-3 beta (GSK-3 β), a key component of Wnt/ β -catenin signal transduction [145]. To date, the clinical application of tideglusib has been attempted for the treatment of progressive supranuclear palsy, congenital/juvenile-onset myotonic muscular dystrophy, and Alzheimer's disease [146–149]. Neves et al. reported that tideglusib treatment of damaged dentin promoted reparative [142] and reactionary dentin formation [143]. In addition, Wnt-responsive pulpal SSPCs in the molars were detected as Axin2⁺ cells in Axin2-CreER^{T2} mice [141]. These Axin2⁺ SSPCs differentiate into odontoblast-like cells in response to dental damage by activating their own Wnt signaling pathway in an autocrine manner and contribute to reparative dentin formation. In addition to Axin2⁺ populations, alpha-smooth muscle actin (α SMA)-CreER^{T2} labeling is recommended for pulpal SSPCs [150–152]. Furthermore, the cell-rich zones adjacent to the odontoblast layer detected with Nes-GFP have been suggested to be fractions that contribute to dentin repair in molars [153–157]. It has been suggested that there is a hierarchical relationship between these pulpal cell populations; however, further analyses are needed to answer this question.

6.4. Axin2⁺ SSPCs localized in PDL

Several research groups have detected Axin2⁺ cells in the PDL using Axin2-CreER^{T2} mice and demonstrated their ability to contribute to hard tissue homeostasis. Yuan et al. showed that (1) the PDL-derived Axin2⁺ cells are quiescent in the steady state but proliferate in response to tooth extraction and differentiate into osteoblasts that contribute to socket healing [158], and (2) during the process of immediate post-extraction implantation, the PDL-derived Axin2⁺ cells are responsible for osseointegration [159]. Additionally, Axin2⁺ cells in the PDL have been shown to sense occlusal hyperloading of teeth and contribute to PDL reorganization *via* canonical Wnt signaling [160,161]. It was reported that Axin2⁺ cells in the PDL differentiate into cementoblasts, contribute to root cementum growth [162], and differentiate into osteoblasts and osteocytes on the traction side of the orthodontic treatment [163]. Zhao et al. [164] suggested that during postnatal root formation, both CD90⁺ perivascular cells and Axin2⁺ cells in the PDL give rise to cementoblasts. However, in adult tissues, their sources are limited to Axin2⁺ cells. In contrast, in periodontal disease, the origin of cementoblasts shifted from Axin2⁺ cells to CD90⁺ cells. Taken together, these studies suggest that

the PDL contains diverse origins of hard tissue-forming cells, each of which contributing to the maintenance of dental tissue at the same or different appropriate time points.

7. Conclusions

This review provides an overview of the SSPC population involved in hard tissue formation in both long bones and the oral/cranio-maxillofacial area. It emphasizes the insights gained from employing the Cre/loxP-based cell lineage tracing strategy with LepR-Cre, Gli1-CreER^{T2}, and Axin2-CreER^{T2} mice. In addition to these mouse models, there are useful genetically modified mice that mark the SSPC population. PDL-derived SSPCs have been identified using α SMA-CreER^{T2} [165] and periodontal ligament associated protein-1 (Plap-1)-CreER^{T2} [166]. Alternatively, long bone periosteum SSPCs can be labeled with Cathepsin K (CTSK)-Cre [167]. Notably, the CTSK-Cre and discoidin domain-containing receptor 2-CreER^{T2} labels an independent SSPC population in the calvarial suture [168]. Herein, we focused on DP, PDL, and calvarial suture-derived SSPCs in the oral/maxillofacial region; however, temporomandibular joint-localized SSPC is also an area of interest in this research field. Labeling of the SSPCs localized in the mandibular condylar bone with Sox9-CreER^{T2} has been suggested, and they potentially contribute to jawbone regeneration [169]. These developed cell labeling techniques facilitate an in-depth exploration of cellular dynamics *in vivo*, ultimately revealing the diverse origins of hard tissue-forming cells.

The discussion on the necessity of diverse origins for hard tissue maintenance delves into the intricacies of bone formation processes in different *in vivo* contexts. For instance, rapid bone growth necessitates continuous osteoblast supplementation and activation, while bone tissue in the adult stage relies on remodeling with relatively modest bone formation. Conversely, damaged bone tissues prompt the reactivation of osteoblast supplementation to achieve swift bone healing. To adapt to these varying bone dynamics *in vivo*, the origin and supply system of osteoblasts may be dynamically altered based on the specific hard tissue requirements. Future research endeavors are anticipated to provide further clarity on these adaptive mechanisms. The review speculates on age-related bone loss, proposing that a disruption in the supply system of hard tissue-forming cells, potentially caused by the senescence of SSPCs, could be a contributing factor. Further studies are expected to unveil the intricate regulatory mechanisms governing the supply systems of hard tissue-forming cells responding to diverse tissue environments. The overarching goal is to pave the way for artificially controlling SSPCs, enabling effective bone tissue therapy in clinical settings.

Conflict of interest

The author declares no competing interests.

Acknowledgments

This work was supported by Grants-in-Aid from the Japan Society for the Promotion of Science (JSPS) KAKENHI (23H03072), Tokyo Dental College Research Grant (Well-being Project), the Science Research Promotion Fund from PMAC, Naito Foundation Natural Science, and Takeda Science Foundation to Toshihide Mizoguchi.

References

- [1] Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. *Nature* 2003;423(6937):337–42. <https://doi.org/10.1038/nature01658>. PMID 12748652.
- [2] Zaidi M. Skeletal remodeling in health and disease. *Nat Med* 2007;13(7):791–801. <https://doi.org/10.1038/nm1593>. PMID 17618270.
- [3] Sims NA, Gooi JH. Bone remodeling: multiple cellular interactions required for coupling of bone formation and resorption. *Semin Cell Dev Biol* 2008;19(5):444–51. <https://doi.org/10.1016/j.semcdb.2008.07.016>. PMID 18718546.

- [4] Parfitt AM. Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. *J Cell Biochem* 1994;55(3):273–86. <https://doi.org/10.1002/jcb.240550303>. PMID 7962158.
- [5] Park D, Spencer JA, Koh BI, Kobayashi T, Fujisaki J, Clemens TL, et al. Endogenous bone marrow MSCs are dynamic, fate-restricted participants in bone maintenance and regeneration. *Cell Stem Cell* 2012;10(3):259–72. <https://doi.org/10.1016/j.stem.2012.02.003>. PMID 22385654.
- [6] Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. *Transplantation* 1968;6(2):230–47. <https://doi.org/10.1097/00007890-196803000-00009>. PMID 5654088.
- [7] Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. *Cell Tissue Kinet* 1970;3(4):393–403. <https://doi.org/10.1111/j.1365-2184.1970.tb00347.x>. PMID 5523063.
- [8] Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. *Exp Hematol* 1976;4(5):267–74.
- [9] Friedenstein AJ, Latzinik NW, Grosheva AG, Gorskaya UF. Marrow microenvironment transfer by heterotopic transplantation of freshly isolated and cultured cells in porous sponges. *Exp Hematol* 1982;10(2):217–27.
- [10] Caplan AI. Mesenchymal stem cells. *J Orthop Res* 1991;9(5):641–50. <https://doi.org/10.1002/jor.1100090504>. PMID 1870029.
- [11] Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. *Science* 1999;284(5411):143–7. <https://doi.org/10.1126/science.284.5411.143>. PMID 10102814.
- [12] Horwitz EM, Keating A. Nonhematopoietic mesenchymal stem cells: what are they? *Cytotherapy* 2000;2(5):387–8. <https://doi.org/10.1080/146532400539305>. PMID 12044232.
- [13] Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. *Cytotherapy* 2005;7(5):393–5. <https://doi.org/10.1080/14653240500319234>. PMID 16236628.
- [14] Frenette PS, Pinho S, Lucas D, Scheiermann C. Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine. *Annu Rev Immunol* 2013;31:285–316. <https://doi.org/10.1146/annurev-immunol-032712-095919>. PMID 23298209.
- [15] Bianco P, Robey PG. Skeletal stem cells. In: Lanza, et al., editors. *Handbook of stem cells, two-volume set: volume 1-Embryonic stem cells; volume 2-Adult & fetal stem cells*. Elsevier; 2004. p. 415–25.
- [16] Bianco P, Cao X, Frenette PS, Mao JJ, Robey PG, Simmons PJ, et al. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. *Nat Med* 2013;19(1):35–42. <https://doi.org/10.1038/nm.3028>. PMID 23296015.
- [17] Chan CK, Seo EY, Chen JY, Lo D, McArdle A, Sinha R, et al. Identification and specification of the mouse skeletal stem cell. *Cell* 2015;160(1–2):285–98. <https://doi.org/10.1016/j.cell.2014.12.002>. PMID 25594184.
- [18] Chan CKF, Gulati GS, Sinha R, Tompkins JV, Lopez M, Carter AC, et al. Identification of the human skeletal stem cell. *Cell* 2018;175(1):43–56.e21. <https://doi.org/10.1016/j.cell.2018.07.029>. PMID 30241615.
- [19] Hsu YC. Theory and practice of lineage tracing. *Stem Cells* 2015;33(11):3197–204. <https://doi.org/10.1002/stem.2123>. PMID 26284340.
- [20] Couasnay G, Madel MB, Lim J, Lee B, Eleftheriou F. Sites of Cre-recombinase activity in mouse lines targeting skeletal cells. *J Bone Min Res* 2021;36(9):1661–79. <https://doi.org/10.1002/jbmr.4415>. PMID 34278610.
- [21] Mizoguchi T, Ono N. The diverse origin of bone-forming osteoblasts. *J Bone Min Res* 2021;36(8):1432–47. <https://doi.org/10.1002/jbmr.4410>. PMID 34213032.
- [22] Nakashima M, Reddi AH. The application of bone morphogenetic proteins to dental tissue engineering. *Nat Biotechnol* 2003;21(9):1025–32. <https://doi.org/10.1038/nbt864>. PMID 12949568.
- [23] Zhang YD, Chen Z, Song YQ, Liu C, Chen YP. Making a tooth: growth factors, transcription factors, and stem cells. *Cell Res* 2005;15(5):301–16. <https://doi.org/10.1038/sj.cr.7290299>. PMID 15916718.
- [24] Sharpe PT. Dental mesenchymal stem cells. *Development* 2016;143(13):2273–80. <https://doi.org/10.1242/dev.134189>. PMID 27381225.
- [25] Gould TR, Melcher AH, Brunette DM. Migration and division of progenitor cell populations in periodontal ligament after wounding. *J Periodontol Res* 1980;15(1):20–42. <https://doi.org/10.1111/j.1600-0765.1980.tb00258.x>. PMID 6445968.
- [26] Barrett AP, Reade PC. The relationship between degree of development of tooth isografts and the subsequent formation of bone and periodontal ligament. *J Periodontol Res* 1981;16(4):456–65. <https://doi.org/10.1111/j.1600-0765.1981.tb00996.x>. PMID 6459442.
- [27] Gould TR. Ultrastructural characteristics of progenitor cell populations in the periodontal ligament. *J Dent Res* 1983;62(8):873–6. <https://doi.org/10.1177/00220345830620080401>. PMID 6575034.
- [28] McCulloch CA, Melcher AH. Cell density and cell generation in the periodontal ligament of mice. *Am J Anat* 1983;167(1):43–58. <https://doi.org/10.1002/aja.1001670105>. PMID 6869309.
- [29] Seo BM, Miura M, Gronthos S, Bartold PM, Batouli S, Brahmi J, et al. Investigation of multipotent postnatal stem cells from human periodontal ligament. *Lancet* 2004;364(9429):149–55. [https://doi.org/10.1016/S0140-6736\(04\)16627-0](https://doi.org/10.1016/S0140-6736(04)16627-0). PMID 15246727.
- [30] Matsubara T, Suardita K, Ishii M, Sugiyama M, Igarashi A, Oda R, et al. Alveolar bone marrow as a cell source for regenerative medicine: differences between alveolar and iliac bone marrow stromal cells. *J Bone Min Res* 2005;20(3):399–409. <https://doi.org/10.1359/JBMR.041117>. PMID 15746984.

- [31] Du Y, Jiang F, Liang Y, Wang Y, Zhou W, Pan Y, et al. The angiogenic variation of skeletal site-specific human BMSCs from same alveolar cleft patients: a comparative study. *J Mol Histol* 2016;47(2):153–68. <https://doi.org/10.1007/s10735-016-9662-7>. PMID 26846721.
- [32] Lana-Elola E, Rice R, Grigoriadis AE, Rice DP. Cell fate specification during calvarial bone and suture development. *Dev Biol* 2007;311(2):335–46. <https://doi.org/10.1016/j.ydbio.2007.08.028>. PMID 17931618.
- [33] Ahn S, Joyner AL. Dynamic changes in the response of cells to positive hedgehog signaling during mouse limb patterning. *Cell* 2004;118(4):505–16. <https://doi.org/10.1016/j.cell.2004.07.023>. PMID 15315762.
- [34] DeFalco J, Tomishima M, Liu H, Zhao C, Cai X, Marth JD, et al. Virus-assisted mapping of neural inputs to a feeding center in the hypothalamus. *Science* 2001;291(5513):2608–13. <https://doi.org/10.1126/science.1056602>. PMID 11283374.
- [35] van Amerongen R, Bowman AN, Nusse R. Developmental stage and time dictate the fate of Wnt/beta-catenin-responsive stem cells in the mammary gland. *Cell Stem Cell* 2012;11(3):387–400. <https://doi.org/10.1016/j.stem.2012.05.023>. PMID 22863533.
- [36] Friedrich G, Soriano P. Promoter traps in embryonic stem cells: a genetic screen to identify and mutate developmental genes in mice. *Genes Dev* 1991;5(9):1513–23. <https://doi.org/10.1101/gad.5.9.1513>. PMID 1653172.
- [37] Zambrowicz BP, Imamoto A, Fiering S, Herzenberg LA, Kerr WG, Soriano P. Disruption of overlapping transcripts in the ROSA beta geo 26 gene trap strain leads to widespread expression of beta-galactosidase in mouse embryos and hematopoietic cells. *Proc Natl Acad Sci USA* 1997;94(8):3789–94. <https://doi.org/10.1073/pnas.94.8.3789>. PMID 9108056.
- [38] Madisen L, Zwingman TA, Sunkin SM, Oh SW, Zariwala HA, Gu H, et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. *Nat Neurosci* 2010;13(1):133–40. <https://doi.org/10.1038/nn.2467>. PMID 20023653.
- [39] Li M, Indra AK, Warot X, Brocard J, Messaddeq N, Kato S, et al. Skin abnormalities generated by temporally controlled RXRalpha mutations in mouse epidermis. *Nature* 2000;407(6804):633–6. <https://doi.org/10.1038/35036595>. PMID 11034212.
- [40] Moore KA, Lemischka IR. Stem cells and their niches. *Science* 2006;311(5769):1880–5. <https://doi.org/10.1126/science.1110542>. PMID 16574858.
- [41] Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. *Blood Cells* 1978;4(1-2):7–25.
- [42] Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. *Cell* 2004;118(2):149–61. <https://doi.org/10.1016/j.cell.2004.07.004>. PMID 15260986.
- [43] Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. *Nature* 2003;425(6960):841–6. <https://doi.org/10.1038/nature02040>. PMID 14574413.
- [44] Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, et al. Identification of the haematopoietic stem cell niche and control of the niche size. *Nature* 2003;425(6960):836–41. <https://doi.org/10.1038/nature02041>. PMID 14574412.
- [45] Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. *Cell* 2005;121(7):1109–21. <https://doi.org/10.1016/j.cell.2005.05.026>. PMID 15989959.
- [46] Kiel MJ, He S, Ashkenazi R, Gentry SN, Teta M, Kushner JA, et al. Haematopoietic stem cells do not asymmetrically segregate chromosomes or retain BrdU. *Nature* 2007;449(7159):238–42. <https://doi.org/10.1038/nature06115>. PMID 17728714.
- [47] Kiel MJ, Radice GL, Morrison SJ. Lack of evidence that hematopoietic stem cells depend on N-cadherin-mediated adhesion to osteoblasts for their maintenance. *Cell Stem Cell* 2007;1(2):204–17. <https://doi.org/10.1016/j.stem.2007.06.001>. PMID 18371351.
- [48] Kiel MJ, Acar M, Radice GL, Morrison SJ. Hemopoietic stem cells do not depend on N-cadherin to regulate their maintenance. *Cell Stem Cell* 2009;4(2):170–9. <https://doi.org/10.1016/j.stem.2008.10.005>. PMID 19119091.
- [49] Méndez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, MacArthur BD, Lira SA, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. *Nature* 2010;466(7308):829–34. <https://doi.org/10.1038/nature09262>. PMID 20703299.
- [50] Ara T, Tokoyoda K, Sugiyama T, Egawa T, Kawabata K, Nagasawa T. Long-term hematopoietic stem cells require stromal cell-derived factor-1 for colonizing bone marrow during ontogeny. *Immunity* 2003;19(2):257–67. [https://doi.org/10.1016/s1074-7613\(03\)00201-2](https://doi.org/10.1016/s1074-7613(03)00201-2). PMID 12932359.
- [51] Omatsu Y, Sugiyama T, Kohara H, Kondoh G, Fujii N, Kohno K, et al. The essential functions of adipo-osteogenic progenitors as the hematopoietic stem and progenitor cell niche. *Immunity* 2010;33(3):387–99. <https://doi.org/10.1016/j.immuni.2010.08.017>. PMID 20850355.
- [52] Sacchetti B, Funari A, Michienzi S, Di Cesare S, Piersanti S, Saggio I, et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. *Cell* 2007;131(2):324–36. <https://doi.org/10.1016/j.cell.2007.08.025>. PMID 17956733.
- [53] Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. *Nature* 1994;372(6505):425–32. <https://doi.org/10.1038/372425a0>. PMID 7984236.
- [54] Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, et al. Identification and expression cloning of a leptin receptor, OB-R. *Cell* 1995;83(7):1263–71. [https://doi.org/10.1016/0092-8674\(95\)90151-5](https://doi.org/10.1016/0092-8674(95)90151-5). PMID 8548812.
- [55] Bates SH, Stearns WH, Dundon TA, Schubert M, Tso AW, Wang Y, et al. STAT3 signalling is required for leptin regulation of energy balance but not reproduction. *Nature* 2003;421(6925):856–9. <https://doi.org/10.1038/nature01388>. PMID 12594516.
- [56] Ding L, Saunders TL, Enikolopov G, Morrison SJ. Endothelial and perivascular cells maintain haematopoietic stem cells. *Nature* 2012;481(7382):457–62. <https://doi.org/10.1038/nature10783>. PMID 22281595.
- [57] Mizoguchi T, Pinho S, Ahmed J, Kunisaki Y, Hanoun M, Mendelson A, et al. Osterix marks distinct waves of primitive and definitive stromal progenitors during bone marrow development. *Dev Cell* 2014;29(3):340–9. <https://doi.org/10.1016/j.devcel.2014.03.013>. PMID 24823377.
- [58] Zhou BO, Yue R, Murphy MM, Peyer JG, Morrison SJ. Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. *Cell Stem Cell* 2014;15(2):154–68. <https://doi.org/10.1016/j.stem.2014.06.008>. PMID 24953181.
- [59] Asada N, Kunisaki Y, Pierce H, Wang Z, Fernandez NF, Birbrair A, et al. Differential cytokine contributions of perivascular haematopoietic stem cell niches. *Nat Cell Biol* 2017;19(3):214–23. <https://doi.org/10.1038/ncb3475>. PMID 28218906.
- [60] Omatsu Y, Seike M, Sugiyama T, Kume T, Nagasawa T. Foxc1 is a critical regulator of haematopoietic stem/progenitor cell niche formation. *Nature* 2014;508(7497):536–40. <https://doi.org/10.1038/nature13071>. PMID 24590069.
- [61] Kunisaki Y, Bruns I, Scheiermann C, Ahmed J, Pinho S, Zhang D, et al. Arteriolar niches maintain haematopoietic stem cell quiescence. *Nature* 2013;502(7473):637–43. <https://doi.org/10.1038/nature12612>. PMID 24107994.
- [62] Ono N, Ono W, Mizoguchi T, Nagasawa T, Frenette PS, Kronenberg HM. Vasculature-associated cells expressing nestin in developing bones encompass early cells in the osteoblast and endothelial lineage. *Dev Cell* 2014;29(3):330–9. <https://doi.org/10.1016/j.devcel.2014.03.014>. PMID 24823376.
- [63] Mizuhashi K, Ono W, Matsushita Y, Sakagami N, Takahashi A, Saunders TL, et al. Resting zone of the growth plate houses a unique class of skeletal stem cells. *Nature* 2018;563(7730):254–8. <https://doi.org/10.1038/s41586-018-0662-5>. PMID 30401834.
- [64] Shu HS, Liu YL, Tang XT, Zhang XS, Zhou B, Zou W, et al. Tracing the skeletal progenitor transition during postnatal bone formation. *Cell Stem Cell* 2021;28(12):2122–2136.e3. <https://doi.org/10.1016/j.stem.2021.08.010>. PMID 34499868.
- [65] Estell EG, Rosen CJ. Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis. *Nat Rev Endocrinol* 2021;17(1):31–46. <https://doi.org/10.1038/s41574-020-00426-5>. PMID 33149262.
- [66] Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. *N Engl J Med* 2001;344(19):1434–41. <https://doi.org/10.1056/NEJM200105103441904>. PMID 11346808.
- [67] Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. *Bone* 2007;40(6):1434–46. <https://doi.org/10.1016/j.bone.2007.03.017>. PMID 17517365.
- [68] Yang M, Arai A, Udagawa N, Hiraga T, Lijuan Z, Ito S, et al. Osteogenic factor Runx2 marks a subset of leptin receptor-positive cells that sit atop the bone marrow stromal cell hierarchy. *Sci Rep* 2017;7(1):4928. <https://doi.org/10.1038/s41598-017-05401-1>. PMID 28694469.
- [69] Yang M, Arai A, Udagawa N, Zhao L, Nishida D, Murakami K, et al. Parathyroid hormone shifts cell fate of a leptin receptor-marked stromal population from adipogenic to osteoblastic lineage. *J Bone Min Res* 2019;34(10):1952–63. <https://doi.org/10.1002/jbmr.3811>. PMID 31173642.
- [70] Fan Y, Hanai JL, Le PT, Bi R, Maridas D, DeMambro V, et al. Parathyroid hormone directs bone marrow mesenchymal cell fate. *Cell Metab* 2017;25(3):661–72. <https://doi.org/10.1016/j.cmet.2017.01.001>. PMID 28162969.
- [71] Yue R, Zhou BO, Shimada IS, Zhao Z, Morrison SJ. Leptin receptor promotes adipogenesis and reduces osteogenesis by regulating mesenchymal stromal cells in adult bone marrow. *Cell Stem Cell* 2016;18(6):782–96. <https://doi.org/10.1016/j.stem.2016.02.015>. PMID 27053299.
- [72] Ducy P, Amling M, Takeda S, Priemel N, Schilling AF, Beil FT, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. *Cell* 2000;100(2):197–207. [https://doi.org/10.1016/s0092-8674\(00\)81558-5](https://doi.org/10.1016/s0092-8674(00)81558-5). PMID 10660043.
- [73] Takeda S, Eleftheriou F, Levasseur R, Liu X, Zhao L, Parker KL, et al. Leptin regulates bone formation via the sympathetic nervous system. *Cell* 2002;111(3):305–17. [https://doi.org/10.1016/s0092-8674\(02\)01049-8](https://doi.org/10.1016/s0092-8674(02)01049-8). PMID 12419242.
- [74] Williams GA, Callon KE, Watson M, Costa JL, Ding Y, Dickinson M, et al. Skeletal phenotype of the leptin receptor-deficient db/db mouse. *J Bone Min Res* 2011;26(8):1698–709. <https://doi.org/10.1002/jbmr.367>. PMID 21328476.
- [75] Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. *Endocrinology* 1999;140(4):1630–8. <https://doi.org/10.1210/endo.140.4.6637>. PMID 10098497.
- [76] Seike M, Omatsu Y, Watanabe H, Kondoh G, Nagasawa T. Stem cell niche-specific Ebf3 maintains the bone marrow cavity. *Genes Dev* 2018;32(5-6):359–72. <https://doi.org/10.1101/gad.311068.117>. PMID 29563184.
- [77] Decker M, Martinez-Morentin L, Wang G, Lee Y, Liu Q, Leslie J, et al. Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis. *Nat Cell Biol* 2017;19(6):677–88. <https://doi.org/10.1038/ncb3530>. PMID 28481328.
- [78] Omatsu Y, Aiba S, Maeta T, Higaki K, Aoki K, Watanabe H, et al. Runx1 and Runx2 inhibit fibrotic conversion of cellular niches for hematopoietic stem cells.

- [125] Yi Y, Stenberg W, Luo W, Feng JQ, Zhao H. Alveolar bone marrow Gli1+ stem cells support implant osseointegration. *J Dent Res* 2022;101(1):73–82. <https://doi.org/10.1177/00220345211013722>. PMID 34009063.
- [126] Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. *Nat Med* 2013;19(2):179–92. <https://doi.org/10.1038/nm.3074>. PMID 23389618.
- [127] Jho EH, Zhang T, Domon C, Joo CK, Freund JN, Costantini F. Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. *Mol Cell Biol* 2002;22(4):1172–83. <https://doi.org/10.1128/MCB.22.4.1172-1183.2002>. PMID 11809808.
- [128] Lustig B, Jerchow B, Sachs M, Weiler S, Pietsch T, Karsten U, et al. Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. *Mol Cell Biol* 2002;22(4):1184–93. <https://doi.org/10.1128/MCB.22.4.1184-1193.2002>. PMID 11809809.
- [129] Bowman AN, van Amerongen R, Palmer TD, Nusse R. Lineage tracing with Axin2 reveals distinct developmental and adult populations of Wnt/beta-catenin-responsive neural stem cells. *Proc Natl Acad Sci USA* 2013;110(18):7324–9. <https://doi.org/10.1073/pnas.1305411110>. PMID 23589866.
- [130] Lim X, Tan SH, Koh WL, Chau RM, Yan KS, Kuo CJ, et al. Interfollicular epidermal stem cells self-renew via autocrine Wnt signaling. *Science* 2013;342(6163):1226–30. <https://doi.org/10.1126/science.1239730>. PMID 24311688.
- [131] Lee SH, Johnson DT, Luong R, Yu EJ, Cunha GR, Nusse R, et al. Wnt/beta-catenin-responsive cells in prostatic development and regeneration. *Stem Cells* 2015;33(11):3356–67. <https://doi.org/10.1002/stem.2096>. PMID 26220362.
- [132] Tan SH, Senarath-Yapa K, Chung MT, Longaker MT, Wu JY, Nusse R. Wnts produced by Osterix-expressing osteolineage cells regulate their proliferation and differentiation. *Proc Natl Acad Sci USA* 2014;111(49):E5262–71. <https://doi.org/10.1073/pnas.1420463111>. PMID 25422448.
- [133] Ransom RC, Hunter DJ, Hyman S, Singh G, Ransom SC, Shen EZ, et al. Axin2-expressing cells execute regeneration after skeletal injury. *Sci Rep* 2016;6:36524. <https://doi.org/10.1038/srep36524>. PMID 27853243.
- [134] Usami Y, Gunawardena AT, Francois NB, Otsuru S, Takano H, Hirose K, et al. Possible contribution of Wnt-responsive chondroprogenitors to the postnatal murine growth plate. *J Bone Min Res* 2019;34(5):964–74. <https://doi.org/10.1002/jbmr.3658>. PMID 30602070.
- [135] Maruyama T, Jeong J, Sheu TJ, Hsu W. Stem cells of the suture mesenchyme in craniofacial bone development, repair and regeneration. *Nat Commun* 2016;7:10526. <https://doi.org/10.1038/ncomms10526>. PMID 26830436.
- [136] Maruyama T, Stevens R, Boka A, DiRienzo L, Chang C, Yu HI, et al. BMPRIA maintains skeletal stem cell properties in craniofacial development and craniosynostosis. *Sci Transl Med* 2021;13(583). <https://doi.org/10.1126/scitranslmed.abb4416>. PMID 33658353.
- [137] Reya T, Clevers H. Wnt signalling in stem cells and cancer. *Nature* 2005;434(7035):843–50. <https://doi.org/10.1038/nature03319>. PMID 15829953.
- [138] Clevers H. Wnt/beta-catenin signaling in development and disease. *Cell* 2006;127(3):469–80. <https://doi.org/10.1016/j.cell.2006.10.018>. PMID 17081971.
- [139] Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. *Cell* 2012;149(6):1192–205. <https://doi.org/10.1016/j.cell.2012.05.012>. PMID 22682243.
- [140] Hunter DJ, Bardet C, Mouraret S, Liu B, Singh G, Sadoine J, et al. Wnt acts as a prosurvival signal to enhance dentin regeneration. *J Bone Min Res* 2015;30(7):1150–9. <https://doi.org/10.1002/jbmr.2444>. PMID 25556760.
- [141] Babb R, Chandrasekaran D, Carvalho Moreno Neves V, Sharpe PT. Axin2-expressing cells differentiate into reparative odontoblasts via autocrine Wnt/beta-catenin signaling in response to tooth damage. *Sci Rep* 2017;7(1):3102. <https://doi.org/10.1038/s41598-017-03145-6>. PMID 28596530.
- [142] Neves VC, Babb R, Chandrasekaran D, Sharpe PT. Promotion of natural tooth repair by small molecule GSK3 antagonists. *Sci Rep* 2017;7:39654. <https://doi.org/10.1038/srep39654>. PMID 28067250.
- [143] Neves VCM, Sharpe PT. Regulation of reactionary dentine formation. *J Dent Res* 2018;97(4):416–22. <https://doi.org/10.1177/0022034517743431>. PMID 29185832.
- [144] Zhao Y, Yuan X, Liu B, Tulu US, Helms JA. Wnt-responsive odontoblasts secrete new dentin after superficial tooth injury. *J Dent Res* 2018;97(9):1047–54. <https://doi.org/10.1177/0022034518763151>. PMID 29566345.
- [145] Pandey MK, DeGrado TR. Glycogen synthase Kinase-3 (GSK-3)-targeted therapy and imaging. *Theranostics* 2016;6(4):571–93. <https://doi.org/10.7150/thno.14334>. PMID 26941849.
- [146] Del Ser T, Steinwachs KC, Gertz HJ, Andrés MV, Gómez-Carrillo B, Medina M, et al. Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. *J Alzheimers Dis* 2013;33(1):205–15. <https://doi.org/10.3233/JAD-2012-120805>. PMID 22936007.
- [147] Tolosa E, Litvan I, Höglinger GU, Burn D, Lees A, Andrés MV, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. *Mov Disord* 2014;29(4):470–8. <https://doi.org/10.1002/mds.25824>. PMID 24532007.
- [148] Lovestone S, Boada M, Dubois B, Hüll M, Rinne JO, Huppertz HJ, et al. A phase II trial of tideglusib in Alzheimer's disease. *J Alzheimers Dis* 2015;45(1):75–88. <https://doi.org/10.3233/JAD-141959>. PMID 25537011.
- [149] Horrigan J, Gomes TB, Snape M, Nikolenko N, McMorn A, Evans S, et al. A Phase 2 study of AMO-02 (tideglusib) in congenital and childhood-onset Myotonic dystrophy Type 1 (DM1). *Pedia Neurol* 2020;112:84–93. <https://doi.org/10.1016/j.pediatrneurol.2020.08.001>. PMID 32942085.
- [150] Grcevic D, Pejda S, Matthews BG, Repic D, Wang L, Li H, et al. In vivo fate mapping identifies mesenchymal progenitor cells. *Stem Cells* 2012;30(2):187–96. <https://doi.org/10.1002/stem.780>. PMID 22083974.
- [151] Vidovic I, Banerjee A, Fatahi R, Matthews BG, Dymont NA, Kalajic I, et al. α SMA-expressing perivascular cells represent dental pulp progenitors in vivo. *J Dent Res* 2017;96(3):323–30. <https://doi.org/10.1177/0022034516678208>. PMID 27834664.
- [152] Vidovic-Zdrilic I, Vining KH, Vijaykumar A, Kalajic I, Mooney DJ, Mina M. FGF2 enhances odontoblast differentiation by α SMA+ progenitors in vivo. *J Dent Res* 2018;97(10):1170–7. <https://doi.org/10.1177/0022034518769827>. PMID 29649366.
- [153] Zhao L, Ito S, Arai A, Udagawa N, Horibe K, Hara M, et al. Odontoblast death drives cell-rich zone-derived dental tissue regeneration. *Bone* 2021;150:116010. <https://doi.org/10.1016/j.bone.2021.116010>. PMID 34020080.
- [154] Harada M, Kenmotsu S, Nakasone N, Nakakura-Ohshima K, Ohshima H. Cell dynamics in the pulpal healing process following cavity preparation in rat molars. *Histochem Cell Biol* 2008;130(4):773–83. <https://doi.org/10.1007/s00418-008-0438-3>. PMID 18463888.
- [155] Hosoya A, Hiraga T, Ninomiya T, Yukita A, Yoshida K, Yoshida N, et al. Thy-1-positive cells in the subodontoblastic layer possess high potential to differentiate into hard tissue-forming cells. *Histochem Cell Biol* 2012;137(6):733–42. <https://doi.org/10.1007/s00418-012-0928-1>. PMID 22327831.
- [156] Nakatomi M, Quispe-Salcedo A, Sakaguchi M, Ida-Yonemochi H, Okano H, Ohshima H. Nestin expression is differentially regulated between odontoblasts and the subodontoblastic layer in mice. *Histochem Cell Biol* 2018;149(4):383–91. <https://doi.org/10.1007/s00418-018-1651-3>. PMID 29445893.
- [157] Hosoya A, Nakamura H, Ninomiya T, Hoshi K, Yoshida K, Yoshida N, et al. Hard tissue formation in subcutaneously transplanted rat dental pulp. *J Dent Res* 2007;86(5):469–74. <https://doi.org/10.1177/154405910708600515>. PMID 17452570.
- [158] Yuan X, Pei X, Zhao Y, Tulu US, Liu B, Helms JA. A Wnt-responsive PDL population effectuates extraction socket healing. *J Dent Res* 2018;97(7):803–9. <https://doi.org/10.1177/0022034518755719>. PMID 29420105.
- [159] Yuan X, Pei X, Zhao Y, Li Z, Chen CH, Tulu US, et al. Biomechanics of immediate postextraction implant osseointegration. *J Dent Res* 2018;97(9):987–94. <https://doi.org/10.1177/0022034518765757>. PMID 29608868.
- [160] Xu Q, Yuan X, Zhang X, Chen J, Shi Y, Brunski JB, et al. Mechanoadaptive responses in the periodontium are Coordinated by Wnt. *J Dent Res* 2019;98(6):689–97. <https://doi.org/10.1177/0022034519839438>. PMID 30971171.
- [161] Zhang X, Yuan X, Xu Q, Arioka M, Van Brunt LA, Shi Y, et al. Molecular basis for periodontal ligament adaptation to in vivo loading. *J Dent Res* 2019;98(3):331–8. <https://doi.org/10.1177/0022034518817305>. PMID 30612508.
- [162] Xie X, Wang J, Wang K, Li C, Zhang S, Jing D, et al. Axin2+ mesenchymal PDL cells, instead of K14(+) epithelial cells, play a key role in rapid cementum growth. *J Dent Res* 2019;98(11):1262–70. <https://doi.org/10.1177/0022034519871021>. PMID 31454276.
- [163] Wang K, Xu C, Xie X, Jing Y, Chen PJ, Yadav S, et al. Axin2+ PDL cells directly contribute to new alveolar bone formation in response to orthodontic tension force. *J Dent Res* 2022;101(6):695–703. <https://doi.org/10.1177/00220345211062585>. PMID 35001706.
- [164] Zhao J, Faure L, Adameyko I, Sharpe PT. Stem cell contributions to cementoblast differentiation in healthy periodontal ligament and periodontitis. *Stem Cells* 2021;39(1):92–102. <https://doi.org/10.1002/stem.3288>. PMID 33038290.
- [165] Roguljic H, Matthews BG, Yang W, Cvija H, Mina M, Kalajic I. In vivo identification of periodontal progenitor cells. *J Dent Res* 2013;92(8):709–15. <https://doi.org/10.1177/0022034513493434>. PMID 23735585.
- [166] Iwayama T, Iwashita M, Miyashita K, Sakashita H, Matsumoto S, Tomita K, et al. Plap-1 lineage tracing and single-cell transcriptomics reveal cellular dynamics in the periodontal ligament. *Development* 2022;149(19). <https://doi.org/10.1242/dev.201203>. PMID 36245218.
- [167] Debnath S, Yallowitz AR, McCormick J, Lalani S, Zhang T, Xu R, et al. Discovery of a periosteal stem cell mediating intramembranous bone formation. *Nature* 2018;562(7725):133–9. <https://doi.org/10.1038/s41586-018-0554-8>. PMID 30250253.
- [168] Bok S, Yallowitz AR, Sun J, McCormick J, Cung M, Hu L, et al. A multi-stem cell basis for craniosynostosis and calvarial mineralization. *Nature* 2023;621(7980):804–12. <https://doi.org/10.1038/s41586-023-06526-2>. PMID 37730988.
- [169] Ransom RC, Carter AC, Salhotra A, Leavitt T, Marecic O, Murphy MP, et al. Mechanoresponsive stem cells acquire neural crest fate in jaw regeneration. *Nature* 2018;563(7732):514–21. <https://doi.org/10.1038/s41586-018-0650-9>. PMID 30356216.